Advances in pediatric rhabdomyosarcoma characterization and disease model development

Histology and Histopathology

Volumn 27, Issue 1, 2012, Pages 13-22

  O'Brien, Dennis ^a   Jacob, Aishwarya G ^a   Qualman, Stephen J ^a   Chandler, Dawn S ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Mouse models; RMS subtypes; Sarcoma

Indexed keywords

AGE; ANIMAL; CHILD; CLASSIFICATION; DISEASE MODEL; DRUG SCREENING; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; MALE; METABOLISM; MOUSE; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; REVIEW; RHABDOMYOSARCOMA; RISK FACTOR; TRANSGENIC ANIMAL;

AGE FACTORS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CHILD; CHILD, PRESCHOOL; DISEASE MODELS, ANIMAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICE; PROGNOSIS; RHABDOMYOSARCOMA; RISK FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 82755196331     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Anderson M.J., Shelton G.D., Cavenee W.K. and Arden K.C. (2001). Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. Proc. Natl. Acad. Sci. USA 98, 1589-1594.
2. Bartel F., Taylor A.C., Taubert H. and Harris L.C. (2001a). Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines. Oncol. Res. 12, 451-457.
3. Bartel F., Meye A., Wurl P., Kappler M., Bache M., Lautenschlager C., Grunbaum U., Schmidt H. and Taubert H. (2001b). Amplification of the MDM2 gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcoma. Int. J. Cancer 95, 168-175.
4. Bartel F., Schulz J., Bohnke A., Blumke K., Kappler M., Bache M., Schmidt H., Wurl P., Taubert H. and Hauptmann S. (2005). Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis. Int. J. Cancer 117, 469-475.
5. Bennicelli J.L., Fredericks W.J., Wilson R.B., Rauscher F.J. 3rd and Barr F.G. (1995). Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. Oncogene 11, 119-130.
6. Breneman J.C., Lyden E., Pappo A.S., Link M.P., Anderson J.R., Parham D.M., Qualman S.J., Wharam M.D., Donaldson S.S., Maurer H.M., Meyer W.H., Baker K.S., Paidas C.N. and Crist W.M. (2003). Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV. J. Clin. Oncol. 21, 78-84.
7. Bridge J.A., Liu J., Qualman S.J., Suijkerbuijk R., Wenger G., Zhang J., Wan X., Baker K.S., Sorensen P. and Barr F.G. (2002). Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes. Genes Chromosomes Cancer 33, 310-321.
8. Cam H., Griesmann H., Beitzinger M., Hofmann L., Beinoraviciute-Kellner R., Sauer M., Huttinger-Kirchhof N., Oswald C., Friedl P., Gattenlohner S., Burek C., Rosenwald A. and Stiewe T. (2006). p53 family members in myogenic differentiation and rhabdomyosarcoma development. Cancer Cell 10, 281-293.
9. Chamberlain J.S., Metzger J., Reyes M., Townsend D. and Faulkner J.A. (2007). Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J. 21, 2195-2204.
10. Chandler D.S., Singh R.K., Caldwell L.C., Bitler J.L. and Lozano G. (2006). Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res. 66, 9502-9508.
11. Daston G., Lamar E., Olivier M. and Goulding M. (1996). Pax-3 is necessary for migration but not differentiation of limb muscle precursors in the mouse. Development 122, 1017-1027.
12. Dias P., Kumar P., Marsden H.B., Gattamaneni H.R., Heighway J. and Kumar S. (1990). N-myc gene is amplified in alveolar rhabdomyosarcomas (RMS) but not in embryonal RMS. Int. J. Cancer 45, 593-596.
13. Diller L., Sexsmith E., Gottlieb A., Li F.P. and Malkin D. (1995). Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J. Clin. Invest. 95, 1606-1611.
14. Doyle B., Morton J.P., Delaney D.W., Ridgway R.A., Wilkins J.A. and Sansom O.J. (2010). p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. J. Pathol. 222, 129-137.
15. Driman D., Thorner P.S., Greenberg M.L., Chilton-MacNeill S. and Squire J. (1994). Mycn gene amplification in rhabdomyosarcoma. Cancer 73, 2231-2237.
16. Durbin A.D., Somers G.R., Forrester M., Pienkowska M., Hannigan G.E. and Malkin D. (2009). JNK1 determines the oncogenic or tumorsuppressive activity of the integrin-linked kinase in human rhabdomyosarcoma. J. Clin. Invest. 119, 1558-1570.
17. Evans S.C., Viswanathan M., Grier J.D., Narayana M., El-Naggar A.K. and Lozano G. (2001). An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 20, 4041-4049.
18. Felix C.A., Kappel C.C., Mitsudomi T., Nau M.M., Tsokos M., Crouch G.D., Nisen P.D., Winick N.J. and Helman L.J. (1992). Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res. 52, 2243-2247.
19. Fernandez K., Serinagaoglu Y., Hammond S., Martin L.T. and Martin P.T. (2010). Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancerassociated p53 mutations and alternatively spliced or mutant Mdm2 transcripts. Am. J. Pathol. 176, 416-434.
20. Fleischmann A., Jochum W., Eferl R., Witowsky J. and Wagner E.F. (2003). Rhabdomyosarcoma development in mice lacking Trp53 and Fos: Tumor suppression by the Fos protooncogene. Cancer Cell 4, 477-482.
21. Gaiger A.M., Soule E.H. and Newton W.A. Jr. (1981). Pathology of rhabdomyosarcoma: Experience of the Intergroup Rhabdomyosarcoma Study, 1972-78. Natl. Cancer. Inst. Monogr. 19-27.
22. Galindo R.L., Allport J.A. and Olson E.N. (2006). A Drosophila model of the rhabdomyosarcoma initiator PAX7-FKHR. Proc. Natl. Acad. Sci. USA 103, 13439-13444.
23. Giglio S., Mancini F., Gentiletti F., Sparaco G., Felicioni L., Barassi F., Martella C., Prodosmo A., Iacovelli S., Buttitta F., Farsetti A., Soddu S., Marchetti A., Sacchi A., Pontecorvi A. and Moretti F. (2005). Identification of an aberrantly spliced form of HDMX in human tumors: A new mechanism for HDM2 stabilization. Cancer Res. 65, 9687-9694.
24. Hachitanda Y., Toyoshima S., Akazawa K. and Tsuneyoshi M. (1998). N-myc gene amplification in rhabdomyosarcoma detected by fluorescence in situ hybridization: Its correlation with histologic features. Mod. Pathol. 11, 1222-1227.
25. Houghton P.J., Morton C.L., Tucker C., Payne D., Favours E., Cole C., Gorlick R., Kolb E.A., Zhang W., Lock R., Carol H., Tajbakhsh M., Reynolds C.P., Maris J.M., Courtright J., Keir S.T., Friedman H.S., Stopford C., Zeidner J., Wu J., Liu T., Billups C.A., Khan J., Ansher S., Zhang J. and Smith M.A. (2007). The pediatric preclinical testing program: Description of models and early testing results. Pediatr. Blood Cancer 49, 928-940.
26. Houghton P.J., Morton C.L., Kolb E.A., Gorlick R., Lock R., Carol H., Reynolds C.P., Maris J.M., Keir S.T., Billups C.A. and Smith M.A. (2008). Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr. Blood Cancer 50, 799-805.
27. Houghton P.J., Morton C.L., Gorlick R., Kolb E.A., Keir S.T., Reynolds C.P., Kang M.H., Maris J.M., Wu J. and Smith M.A. (2010). Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 54, 921-926.
28. Iolascon A., Faienza M.F., Coppola B., Rosolen A., Basso G., Della Ragione F. and Schettini F. (1996). Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma. Genes Chromosomes Cancer 15, 217-222.
29. Keleti J., Quezado M.M., Abaza M.M., Raffeld M. and Tsokos M. (1996). The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am. J. Pathol. 149, 143-151.
30. Keller C., Hansen M.S., Coffin C.M. and Capecchi M.R. (2004a). Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin. Genes Dev. 18, 2608-2613.
31. Keller C., Arenkiel B.R., Coffin C.M., El-Bardeesy N., DePinho R.A. and Capecchi M.R. (2004b). Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: Cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev. 18, 2614-2626.
32. Kelly K.M., Womer R.B., Sorensen P.H., Xiong Q.B. and Barr F.G. (1997). Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. J. Clin. Oncol. 15, 1831-1836.
33. Khatib Z.A., Matsushime H., Valentine M., Shapiro D.N., Sherr C.J. and Look A.T. (1993). Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res. 53, 5535-5541.
34. Kobbert C., Mollmann C., Schafers M., Hermann S., Baba H.A., Hoffmeier A., Breithardt G., Scheld H.H., Weissen-Plenz G. and Sindermann J.R. (2008). Transgenic model of cardiac rhabdomyosarcoma formation. J. Thorac. Cardiovasc. Surg. 136, 1178-1186.
35. Kolb E.A., Gorlick R., Lock R., Carol H., Morton C.L., Keir S.T., Reynolds C.P., Kang M.H., Maris J.M., Billups C., Smith M.A. and Houghton P.J. (2011). Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr. Blood Cancer 56, 595-603.
36. Lagutina I., Conway S.J., Sublett J. and Grosveld G.C. (2002). Pax3-FKHR knock-in mice show developmental aberrations but do not develop tumors. Mol. Cell. Biol. 22, 7204-7216.
37. Langenau D.M., Keefe M.D., Storer N.Y., Guyon J.R., Kutok J.L., Le X., Goessling W., Neuberg D.S., Kunkel L.M. and Zon L.I. (2007). Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev. 21, 1382-1395.
38. Leuschner I., Langhans I., Schmitz R., Harms D., Mattke A. and Treuner J. (2003). p53 and mdm-2 expression in rhabdomyosarcoma of childhood and adolescence: Clinicopathologic study by the Kiel Pediatric Tumor Registry and the German Cooperative Soft Tissue Sarcoma Study. Pediatr. Dev. Pathol. 6, 128-136.
39. Linares L.K., Hengstermann A., Ciechanover A., Muller S. and Scheffner M. (2003). Hdmx stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc. Natl. Acad. Sci. USA 100, 12009-12014.
40. Makawita S., Ho M., Durbin A.D., Thorner P.S., Malkin D. and Somers G.R. (2009). Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors. Pediatr. Dev. Pathol. 12, 127-135.
41. Mao J., Ligon K.L., Rakhlin E.Y., Thayer S.P., Bronson R.T., Rowitch D. and McMahon A.P. (2006). A novel somatic mouse model to survey tumorigenic potential applied to the hedgehog pathway. Cancer Res. 66, 10171-10178.
42. Margue C.M., Bernasconi M., Barr F.G. and Schafer B.W. (2000). Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHR. Oncogene 19, 2921-2929.
43. Matsumoto T., Kinoshita E., Maeda H., Niikawa N., Kurosaki N., Harada N., Yun K., Sawai T., Aoki S., Kondoh T. and Tsuji Y. (1994). Molecular analysis of a patient with Beckwith-Wiedemann syndrome, rhabdomyosarcoma and renal cell carcinoma. Jpn. J. Hum. Genet. 39, 225-234.
44. Matsuoka S., Thompson J.S., Edwards M.C., Bartletta J.M., Grundy P., Kalikin L.M., Harper J.W., Elledge S.J. and Feinberg A.P. (1996). Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15. Proc. Natl. Acad. Sci. USA 93, 3026-3030.
45. Meza J.L., Anderson J., Pappo A.S. and Meyer W.H. (2006). Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: The Children's Oncology Group. J. Clin. Oncol. 24, 3844-3851.
46. Minniti C.P., Tsokos M., Newton W.A. Jr. and Helman L.J. (1994). Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells. Am. J. Clin. Pathol. 101, 198-203.
47. Nanni P., Nicoletti G., De Giovanni C., Croci S., Astolfi A., Landuzzi L., Di Carlo E., Iezzi M., Musiani P. and Lollini P.L. (2003). Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. Cancer Res. 63, 2728-2732.
48. Neale G., Su X., Morton C.L., Phelps D., Gorlick R., Lock R.B., Reynolds C.P., Maris J.M., Friedman H.S., Dome J., Khoury J., Triche T.J., Seeger R.C., Gilbertson R., Khan J., Smith M.A. and Houghton P.J. (2008). Molecular characterization of the pediatric preclinical testing panel. Clin. Cancer Res. 14, 4572-4583.
49. Nishijo K., Chen Q.R., Zhang L., McCleish A.T., Rodriguez A., Cho M.J., Prajapati S.I., Gelfond J.A., Chisholm G.B., Michalek J.E., Aronow B.J., Barr F.G., Randall R.L., Ladanyi M., Qualman S.J., Rubin B.P., LeGallo R.D., Wang C., Khan J. and Keller C. (2009). Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. Cancer Res. 69, 2902-2911.
50. Prodosmo A., Giglio S., Moretti S., Mancini F., Barbi F., Avenia N., Di Conza G., Schunemann H.J., Pistola L., Ludovini V., Sacchi A., Pontecorvi A., Puxeddu E. and Moretti F. (2008). Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties. J. Mol. Med. 86, 585-96.
51. Qualman S.J., Coffin C.M., Newton W.A., Hojo H., Triche T.J., Parham D.M. and Crist W.M. (1998). Intergroup Rhabdomyosarcoma Study: Update for pathologists. Pediatr. Dev. Pathol. 1, 550-561.
52. Qualman S., Lynch J., Bridge J., Parham D., Teot L., Meyer W. and Pappo A. (2008). Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Cancer 113, 3242-3247.
53. Ragazzini P., Gamberi G., Pazzaglia L., Serra M., Magagnoli G., Ponticelli F., Ferrari C., Ghinelli C., Alberghini M., Bertoni F., Picci P. and Benassi M.S. (2004). Amplification of CDK4, MDM2, SAS and GLI genes in leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma. Histol. Histopathol. 19, 401-411.
54. Relaix F., Polimeni M., Rocancourt D., Ponzetto C., Schafer B.W. and Buckingham M. (2003). The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo. Genes Dev. 17, 2950-2965.
55. Ruymann F.B. and Grovas A.C. (2000). Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas. Cancer Invest. 18, 223-241.
56. Sharp R., Recio J.A., Jhappan C., Otsuka T., Liu S., Yu Y., Liu W., Anver M., Navid F., Helman L.J., DePinho R.A. and Merlino G. (2002). Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat. Med. 8, 1276-1280.
57. Smith A.C., Squire J.A., Thorner P., Zielenska M., Shuman C., Grant R., Chitayat D., Nishikawa J.L. and Weksberg R. (2001). Association of alveolar rhabdomyosarcoma with the Beckwith-Wiedemann syndrome. Pediatr. Dev. Pathol. 4, 550-558.
58. Sorensen P.H., Lynch J.C., Qualman S.J., Tirabosco R., Lim J.F., Maurer H.M., Bridge J.A., Crist W.M., Triche T.J. and Barr F.G. (2002). PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: A report from the children's oncology group. J. Clin. Oncol. 20, 2672-2679.
59. Stad R., Little N.A., Xirodimas D.P., Frenk R., van der Eb A.J., Lane D.P., Saville M.K. and Jochemsen A.G. (2001). Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep. 2, 1029-1034.
60. Steinman H.A., Burstein E., Lengner C., Gosselin J., Pihan G., Duckett C.S. and Jones S.N. (2004). An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis. J. Biol. Chem. 279, 4877-4886.
61. Stratton M.R., Fisher C., Gusterson B.A. and Cooper C.S. (1989). Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res. 49, 6324-6327.
62. Sung L., Anderson J.R., Arndt C., Raney R.B., Meyer W.H. and Pappo A.S. (2004). Neurofibromatosis in children with Rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma study IV. J. Pediatr. 144, 666-668.
63. Takahashi Y., Oda Y., Kawaguchi K., Tamiya S., Yamamoto H., Suita S. and Tsuneyoshi M. (2004). Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma. Mod. Pathol. 17, 660-669.
64. Taylor A.C., Shu L., Danks M.K., Poquette C.A., Shetty S., Thayer M.J., Houghton P.J. and Harris L.C. (2000). P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med. Pediatr. Oncol. 35, 96-103.
65. Tsumura H., Yoshida T., Saito H., Imanaka-Yoshida K. and Suzuki N. (2006). Cooperation of oncogenic k-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice. Oncogene 25, 7673-7679.
66. Williamson D., Lu Y.J., Gordon T., Sciot R., Kelsey A., Fisher C., Poremba C., Anderson J., Pritchard-Jones K. and Shipley J. (2005). Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J. Clin. Oncol. 23, 880-888.
67. Williamson D., Selfe J., Gordon T., Lu Y.J., Pritchard-Jones K., Murai K., Jones P., Workman P. and Shipley J. (2007). Role for amplification and expression of glypican-5 in rhabdomyosarcoma. Cancer Res. 67, 57-65.
68. Xia S.J., Pressey J.G. and Barr F.G. (2002). Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol. Ther. 1, 97-104.
69. Yoo J. and Robinson R.A. (1999). H-ras and K-ras mutations in soft tissue sarcoma: Comparative studies of sarcomas from Korean and American patients. Cancer 86, 58-63.